Pathology: Granulocyte colony-stimulating factor has no adverse effects on atherosclerotic lesions in high cholesterol-fed miniature swine
-
- TAKAI Hirotake
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
-
- MIYOSHI Akio
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
-
- YAMAZAKI Masaki
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
-
- ADACHI Kenji
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
-
- KATAGIRI Kouichi
- Chugai Research Institute for Medical Science, Inc.
-
- ARAKAWA Hitoshi
- Chugai Research Institute for Medical Science, Inc.
-
- KATSUYAMA Kiyoka
- Chugai Research Institute for Medical Science, Inc.
-
- ITO Tsuneo
- Chugai Research Institute for Medical Science, Inc.
-
- FUJII Etsuko
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
-
- HAYASHI Shuji
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
-
- KATO Atsuhiko
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
-
- SUZUKI Masami
- Department of Safety Assessment, Fuji Gotemba Research Laboratory, Chugai Pharmaceutical Co., Ltd.
書誌事項
- タイトル別名
-
- Granulocyte Colony-Stimulating Factor Has No Adverse Effects on Atherosclerotic Lesions in High Cholesterol-Fed Miniature Swine
この論文をさがす
抄録
Granulocyte colony-stimulating factor (G-CSF) is widely used to mobilize peripheral blood stem cells, and expected to restore cardiac function for patients with coronary artery diseases as a consequence of progression of atherosclerosis. Safety issues related to the administration of G-CSF to these patients, however, are still under study. The animal model for atherosclerosis was produced by feeding miniature swine a high-cholesterol diet for 3 months. G-CSF (5 or 10 μg/kg/day) was given to the animal model by daily subcutaneous injections for 10 days and 20 main arteries were evaluated pathologically. In addition, the general toxicological effects were studied on clinical signs, body weight, hematology, blood chemistry and pathology. In the G-CSF-treated groups, a variety of changes related to the major pharmacological activity of G-CSF including an increase in white blood cell (WBC) counts were observed. In many arteries, atherosclerotic lesions similar to Type I-V of the proposed classification by the American Heart Association were observed. No effects of the G-CSF treatment were seen on the histopathological findings, incidence, severity or distribution of atherosclerotic lesions. In addition, no infiltration of neutrophils to the lesions was observed. These findings suggest that the administration of G-CSF causes neither exacerbation or modification of atherosclerotic lesions nor adverse changes despite that a sufficient increase in WBC counts could be achieved in the peripheral blood.<br>
収録刊行物
-
- The Journal of Veterinary Medical Science
-
The Journal of Veterinary Medical Science 70 (9), 943-950, 2008
公益社団法人 日本獣医学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681405459328
-
- NII論文ID
- 110006946010
-
- NII書誌ID
- AA10796138
-
- COI
- 1:STN:280:DC%2BD1cnksl2qsQ%3D%3D
-
- ISSN
- 13477439
- 09167250
-
- NDL書誌ID
- 9654753
-
- PubMed
- 18840969
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可